286 related articles for article (PubMed ID: 28589736)
1. Development and in vitro characterization of self-emulsifying drug delivery system (SEDDS) for oral opioid peptide delivery.
Zupančič O; Rohrer J; Thanh Lam H; Grießinger JA; Bernkop-Schnürch A
Drug Dev Ind Pharm; 2017 Oct; 43(10):1694-1702. PubMed ID: 28589736
[TBL] [Abstract][Full Text] [Related]
2. Development, in vitro and in vivo evaluation of a self-emulsifying drug delivery system (SEDDS) for oral enoxaparin administration.
Zupančič O; Grieβinger JA; Rohrer J; Pereira de Sousa I; Danninger L; Partenhauser A; Sündermann NE; Laffleur F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2016 Dec; 109():113-121. PubMed ID: 27693677
[TBL] [Abstract][Full Text] [Related]
3. Development and in vitro evaluation of an oral SEDDS for desmopressin.
Zupančič O; Leonaviciute G; Lam HT; Partenhauser A; Podričnik S; Bernkop-Schnürch A
Drug Deliv; 2016 Jul; 23(6):2074-83. PubMed ID: 26923905
[TBL] [Abstract][Full Text] [Related]
4. Trypsin decorated self-emulsifying drug delivery systems (SEDDS): Key to enhanced mucus permeation.
Shahzadi I; Dizdarević A; Efiana NA; Matuszczak B; Bernkop-Schnürch A
J Colloid Interface Sci; 2018 Dec; 531():253-260. PubMed ID: 30036849
[TBL] [Abstract][Full Text] [Related]
5. Self-emulsifying drug delivery systems: Design of a novel vaginal delivery system for curcumin.
Köllner S; Nardin I; Markt R; Griesser J; Prüfert F; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2017 Jun; 115():268-275. PubMed ID: 28323109
[TBL] [Abstract][Full Text] [Related]
6. Highly mucus permeating and zeta potential changing self-emulsifying drug delivery systems: A potent gene delivery model for causal treatment of cystic fibrosis.
Griesser J; Hetényi G; Federer C; Steinbring C; Ellemunter H; Niedermayr K; Bernkop-Schnürch A
Int J Pharm; 2019 Feb; 557():124-134. PubMed ID: 30594687
[TBL] [Abstract][Full Text] [Related]
7. Development and in vitro characterisation of an oral self-emulsifying delivery system for daptomycin.
Zupančič O; Partenhauser A; Lam HT; Rohrer J; Bernkop-Schnürch A
Eur J Pharm Sci; 2016 Jan; 81():129-36. PubMed ID: 26485536
[TBL] [Abstract][Full Text] [Related]
8. Development and in vitro evaluation of a self-emulsifying drug delivery system (SEDDS) for oral vancomycin administration.
Zaichik S; Steinbring C; Caliskan C; Bernkop-Schnürch A
Int J Pharm; 2019 Jan; 554():125-133. PubMed ID: 30408530
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Hintzen F; Perera G; Hauptstein S; Müller C; Laffleur F; Bernkop-Schnürch A
Int J Pharm; 2014 Sep; 472(1-2):20-6. PubMed ID: 24879935
[TBL] [Abstract][Full Text] [Related]
10. Formulation and in vitro evaluation of self-emulsifying formulations of Cinnarizine.
Vithlani S; Sarraf S; Chaw CS
Drug Dev Ind Pharm; 2012 Oct; 38(10):1188-94. PubMed ID: 22196372
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of self-emulsifying drug delivery systems for oral insulin delivery using an in vitro model simulating the intestinal proteolysis.
Liu J; Hirschberg C; Fanø M; Mu H; Müllertz A
Eur J Pharm Sci; 2020 Apr; 147():105272. PubMed ID: 32084584
[TBL] [Abstract][Full Text] [Related]
12. Mucus permeating thiolated self-emulsifying drug delivery systems.
Rohrer J; Partenhauser A; Hauptstein S; Gallati CM; Matuszczak B; Abdulkarim M; Gumbleton M; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2016 Jan; 98():90-7. PubMed ID: 26598209
[TBL] [Abstract][Full Text] [Related]
13. Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
Bhattacharyya A; Bajpai M
Curr Drug Deliv; 2013 Oct; 10(5):542-7. PubMed ID: 23675913
[TBL] [Abstract][Full Text] [Related]
14. Improved Intestinal Mucus Permeation of Vancomycin via Incorporation Into Nanocarrier Containing Papain-Palmitate.
Efiana NA; Dizdarević A; Huck CW; Bernkop-Schnürch A
J Pharm Sci; 2019 Oct; 108(10):3329-3339. PubMed ID: 31136766
[TBL] [Abstract][Full Text] [Related]
15. Impact of lipases on the protective effect of SEDDS for incorporated peptide drugs towards intestinal peptidases.
Leonaviciute G; Zupančič O; Prüfert F; Rohrer J; Bernkop-Schnürch A
Int J Pharm; 2016 Jul; 508(1-2):102-8. PubMed ID: 27143595
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of an oral self-emulsifying drug delivery system (SEDDS) for exenatide.
Menzel C; Holzeisen T; Laffleur F; Zaichik S; Abdulkarim M; Gumbleton M; Bernkop-Schnürch A
J Control Release; 2018 May; 277():165-172. PubMed ID: 29574041
[TBL] [Abstract][Full Text] [Related]
17. Hydrophobic ion pairing of a GLP-1 analogue for incorporating into lipid nanocarriers designed for oral delivery.
Ismail R; Phan TNQ; Laffleur F; Csóka I; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2020 Jul; 152():10-17. PubMed ID: 32371152
[TBL] [Abstract][Full Text] [Related]
18. Development and in vitro evaluation of zeta potential changing self-emulsifying drug delivery systems for enhanced mucus permeation.
Suchaoin W; Pereira de Sousa I; Netsomboon K; Lam HT; Laffleur F; Bernkop-Schnürch A
Int J Pharm; 2016 Aug; 510(1):255-62. PubMed ID: 27329673
[TBL] [Abstract][Full Text] [Related]
19. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity.
Jain S; Jain AK; Pohekar M; Thanki K
Free Radic Biol Med; 2013 Dec; 65():117-130. PubMed ID: 23792276
[TBL] [Abstract][Full Text] [Related]
20. Mucolytic self-emulsifying drug delivery systems (SEDDS) containing a hydrophobic ion-pair of proteinase.
Lam HT; Le NN; Phan TNQ; Bernkop-Schnürch A
Eur J Pharm Sci; 2021 Jul; 162():105658. PubMed ID: 33271277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
